XOMA Corporation (XOMA)
| Previous close | 25.02 |
| Open | 24.88 |
| Bid | 24.52 x 100 |
| Ask | 0.00 x 0 |
| Day's range | 24.52 - 25.19 |
| 52-week range | 13.48 - 27.00 |
| Volume | |
| Avg. volume | 17,703 |
| Market cap | 285.29M |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.04 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | 2.16 (8.56%) |
| Ex-dividend date | 02 Apr 2024 |
| 1y target est | 57.00 |
ZacksCertara, Inc. (CERT) Q1 Earnings Meet Estimates
Certara (CERT) delivered earnings and revenue surprises of 0% and 2.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksXoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireXOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene®, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6%, a potential first-in-category Phase 3-ready candidate for female sexual arousal disorder Bayer HealthCare
